Climb Bio, Inc. (NASDAQ:CLYM – Free Report) – Stock analysts at Leerink Partnrs issued their FY2024 earnings per share (EPS) estimates for shares of Climb Bio in a research note issued to investors on Monday, December 2nd. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings per share of ($1.57) for the year. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. Leerink Partnrs also issued estimates for Climb Bio’s FY2025 earnings at ($0.65) EPS and FY2026 earnings at ($0.82) EPS.
Separately, Leerink Partners initiated coverage on Climb Bio in a report on Monday. They issued an “outperform” rating and a $10.00 target price on the stock.
Climb Bio Stock Performance
Shares of CLYM stock opened at $3.15 on Wednesday. Climb Bio has a 1 year low of $2.35 and a 1 year high of $11.55.
About Climb Bio
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Featured Stories
- Five stocks we like better than Climb Bio
- The 3 Best Blue-Chip Stocks to Buy Now
- Atlas Energy Solutions: A New Star in the SmallCap 600 Index
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 3 Small-Cap Stocks on the Rise With Over 4% Dividend Yields
- How to Choose Top Rated Stocks
- Insiders Keep Buying These Stocks: 2 to Buy, 1 to Avoid
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
